Modality
Cell Therapy
MOA
AHRant
Target
VEGF
Pathway
Ferroptosis
RettRBHemophilia A
Development Pipeline
Preclinical
~Nov 2018
→ ~Feb 2020
Phase 1
May 2020
→ Jul 2027
Phase 1Current
NCT07184721
1,994 pts·Rett
2020-05→2027-07·Recruiting
1,994 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2027-07-211.3y awayPh2 Data· Rett
Trial Timeline
Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3
P1/2
Recruit…
Catalysts
Ph2 Data
2027-07-21 · 1.3y away
Rett
Recruiting|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT07184721 | Phase 1/2 | Rett | Recruiting | 1994 | DOR |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Zanuderotide | Novartis | Phase 1/2 | VEGF | |
| AZN-5978 | AstraZeneca | Phase 2/3 | GIP-R | |
| TAK-8730 | Takeda | Phase 2 | VEGF | |
| GIL-2011 | Gilead Sciences | Preclinical | VEGF | |
| Bemazumab | Regeneron | Phase 1 | VEGF | |
| BII-5449 | Biogen | Phase 3 | FXIa | |
| Pemicapivasertib | Legend Biotech | Phase 3 | VEGF | |
| Sematapinarof | Legend Biotech | NDA/BLA | VEGF | |
| LEG-6533 | Legend Biotech | NDA/BLA | VEGF | |
| Elratapinarof | Halozyme | Phase 2 | C5 |